30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

aap Sales Decline on U.S. Distribution Loss -

aap Implantate reported 3Q19 revenue of €2.8MM (USD $3.1MM), -0.1% vs. 3Q18.


  • The company expects 2019 sales in the range of $12.4MM (+1.7%) to $14.6MM (+20.1%)
  • Decline in the U.S. was characterized as “temporary” due to the termination of a distributor sales relationship; since late September, weekly U.S. sales are growing at double the rate of the prior year
  • Received approval for human clinical study of their silver coating technology for implants and has started generating preclinical data for resorbable magnesium implant technology
  • aap plans to launch the polyaxial LOCTEQ foot and calcaneus system in the U.S. in 2020
  • ORTHOWORLD projects aap Implantate full year 2019 revenue of $12.9MM, +5.8% vs. 2018


ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).

  3Q19 3Q18 $ Chg % Chg
Trauma $3.1 $3.1 $0.0 -0.1%
  9Mo 19 9Mo 18 $ Chg % Chg
Trauma $9.8 $9.3 $0.5 5.6%


ORTHOWORLD estimates sales by geographic region as follows ($MM).

  3Q19 3Q18 $ Chg % Chg
US $0.5 $0.5 $0.0 -3.5%
Ex-US $2.6 $2.6 $0.0 0.6%
Total $3.1 $3.1 $0.0 -0.1%


Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.